

[Marina Biotech](#) | [MRNA](#) | [Summary](#) | [Profile](#)

Marina Biotech – [MRNA](#) - is focused on the discovery and development of novel RNAi-based therapeutics in the area of oncology, bladder and liver cancer.

[The company](#) is exploring the potential of RNAi-based therapeutics through the development of multiple broad-based, state-of-the-art drug discovery platforms built upon industry leading expertise in RNA chemistry, microbiology and oligonucleotide delivery.

Bladder Cancer

Marina Biotech is conducting preclinical studies in bladder cancer utilizing our

tau

RNAi

platform. Bladder cancer ranks as the 4th most common cancer in men, and the 9th leading cause of death in men in the US. Approximately 75% of all bladder cancer cases in the US are in men. In the US, it is currently estimated that on a yearly basis, more than 70,000 new patients will be diagnosed with bladder cancer and approximately 15,000 deaths will occur from bladder cancer.

Liver Cancer

Marina Biotech is utilizing the *tau*RNAi platform in preclinical

studies of hepatocellular carcinoma, more commonly known as liver cancer. Leading causes of liver cancer include viral infection (hepatitis), toxins, and damage to the liver that result in cirrhosis. Worldwide there are more than 500,000 new cases of liver cancer each year. It is currently estimated that in the US, more than 20,000 new cases of liver cancer will be diagnosed and 19,000 deaths are expected to occur due to liver cancer.

The company has partnered with World's leading companies and universities, including University of Michigan and University of Helsinki. The partners include Roche and Novartis.

The stock is trading near 52WK LOWS, may bounce back keep an eye!

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, [MakeMoney!](#)®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.